Andrew C. Adey

Andrew C. Adey

Auto-generated profile, based on publicly available information

Andrew C. Adey

Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2017 in Science
Verified
Journal Article
Closed access
PDF file
JCJunyue Cao
Junyue Cao
JPJonathan S. Packer
Jonathan S. Packer
VRVijay Ramani
Vijay Ramani
DCDarren A. Cusanovich
Darren A. Cusanovich
CHChau Huynh
Chau Huynh
JSJay Shendure
Jay Shendure
Sequencing each cell of the nematode: Single-cell sequencing is challenging owing to the limited biological material available in an individual cell and the high cost of sequencing across multiple cells. Cao et al. developed a two-step combinatorial barcoding method to profile both single-cell and single-nucleus transcriptomes without requiring physical isolation of each cell. The authors profiled almost 50,000 single cells from an individual Caenorhabditis elegans larval stage and were able to identify and recover information from different, even rare, cell types. Science , this issue p. 661

28 September 2018 in Science
Verified
Journal Article
Closed access
PDF file
JCJunyue Cao
Junyue Cao
DCDarren A. Cusanovich
Darren A. Cusanovich
VRVijay Ramani
Vijay Ramani
DADelasa Aghamirzaie
Delasa Aghamirzaie
HPHannah A. Pliner
Hannah A. Pliner
JSJay Shendure
Jay Shendure
Single-cell chromatin and RNA analysis: Single-cell analyses have begun to provide insight into the differences among and within the individual cells that make up a tissue or organism. However, technological barriers owing to the small amount of material present in each single cell have prevented parallel analyses. Cao et al. present sci-CAR, a pooled barcode method that jointly analyzes both the RNA transcripts and chromatin profiles of single cells. By applying sci-CAR to lung adenocarcinoma cells and mouse kidney tissue, the authors demonstrate precision in assessing expression and genome accessibility at a genome-wide scale. The approach provides an improvement over bulk analysis, which can be confounded by differing cellular subgroups. Science , this issue p. 1380

11 November 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
DSDuanchen Sun
Duanchen Sun
XGXiangnan Guan
Xiangnan Guan
AMAmy E. Moran
Amy E. Moran
LWLing-Yun Wu
Ling-Yun Wu
DQDavid Z. Qian
David Z. Qian
ZXZheng Xia
Zheng Xia

30 January 2017 in Nature Methods
Verified
Journal Article
Closed access
PDF file
SVSarah A Vitak
Sarah A Vitak
KTKristof A Torkenczy
Kristof A Torkenczy
JRJimi L Rosenkrantz
Jimi L Rosenkrantz
AFAndrew J Fields
Andrew J Fields
LCLena Christiansen
Lena Christiansen
AAAndrew Adey
Andrew Adey

9 April 2018 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
RMRyan M Mulqueen
Ryan M Mulqueen
DPDmitry Pokholok
Dmitry Pokholok
SNSteven J Norberg
Steven J Norberg
KTKristof A Torkenczy
Kristof A Torkenczy
AFAndrew J Fields
Andrew J Fields
AAAndrew C Adey
Andrew C Adey

26 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
TBTimothy A Bates
Timothy A Bates
HLHans C. Leier
Hans C. Leier
ZLZoe Lyski
Zoe Lyski
SMSavannah K. McBride
Savannah K. McBride
FCFelicity Coulter
Felicity Coulter
FTFikadu Tafesse
Fikadu Tafesse
SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these vaccines provide in the face of emerging variants. Here, we report two demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we evaluate neutralizing antibody titers against SARS-CoV-2 as well as the B.1.1.7 (alpha) and B.1.351 (beta) variants. We show that both B.1.1.7 and B.1.351 are less well neutralized by serum from vaccinated individuals, and that B.1.351, but not B.1.1.7, is less well neutralized by convalescent serum. We also find that the levels of variant-specific anti-spike antibodies are proportional to neutralizing activities. Together, our results demonstrate the escape of the emerging SARS-CoV-2 variants from neutralization by serum antibodies, which may lead to reduced protection from re-infection or increased risk of vaccine breakthrough.